Management of mucopolysaccharidosis type I using enzyme replacement therapy: Egyptian experience
Abstract Background Mucopolysaccharidosis type I (MPS I) is a known autosomal recessive lysosomal-storage disorder. The disease is caused by a deficiency of the alpha-L-iduronidase (IDUA) enzyme, accumulating the glycosaminoglycans (GAGs) in body organs and a wide phenotypic spectrum. Aim of the wor...
Saved in:
| Main Authors: | Ekram Fateen, Sally A. F. El Sahrigy, Mona Ibrahim, Rasha M. Elhossini, Hoda H. Ahmed, Asmaa Esmail, Amira Radwan, Iman Ibrahim Salama, Abeer M. NourElDin Abd ElBaky, Nada Ezzeldin, Azza M. O. Abdel Rahman, Mona Aglan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-03-01
|
| Series: | Egyptian Journal of Medical Human Genetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43042-025-00668-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of a biosimilar laronidase versus the reference laronidase in patients with mucopolysaccharidosis type I
by: Ali Rabbani, et al.
Published: (2025-08-01) -
How Not to Miss the Mild Forms of Mucopolysaccharidosis Type I in Patients With Articular Manifestations of the Disease?
by: Natalia V. Buchinskaya, et al.
Published: (2019-01-01) -
Results of 14-year-long Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II: Clinical Case
by: Natalia V. Zhurkova, et al.
Published: (2023-01-01) -
EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018-04-01) -
Parental perception of treatment options for mucopolysaccharidosis: a survey to bridge the gap for personalized medicine
by: Anna-Maria Wiesinger, et al.
Published: (2025-01-01)